Teleflex Releases White Paper on Reducing PICC-Related Infection and Thrombosis
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, announces the release of a new white paper to aid clinicians in preventing catheter-related infections and thrombosis.
White paper author Nancy Moureau, BSN, RN, CRNI, CPUI, VA-BC, advocates a multi-level preventive approach that includes a controlled release, chlorhexidine-impregnated Peripherally Inserted Central Catheter (PICC) that helps reduce thrombosis and bloodstream infection. The white paper highlights a preliminary report of 88% reduction in bloodstream infections, attributable to use of the ARROW ® PICC with Chlorag + ard ® Technology, at a major Southern California medical center.
The paper, titled “Catheter-Related Infection and Thrombosis: A Proven Relationship. A Review of Innovative PICC Technology to Reduce Catheter-Related Infection and Thrombosis ” can be downloaded at chlorhexidinefacts.com/arrow-picc.html.
“As hospitals face higher expectations for infection control and more federal reporting requirements, they need to adopt a comprehensive approach to preventing central line-associated bloodstream infections,” Moureau said. “This paper is designed to aid clinicians and technology decision makers by outlining the best clinical and financial strategies to prevent both infection and thrombosis in PICCs.” The paper notes that unprotected peripherally inserted central catheters (PICCs) are often thought to be safer, but in fact have rates of bloodstream infections similar to unprotected central venous catheters (CVCs). In addition, PICCs have higher rates of thrombosis. 1 Thrombosis heightens the risk of infection by greatly increasing bacterial colonization. 2,3 The current widespread use of PICCs increases these concerns, with more than 2 million PICCs placed per year in the U.S., according to Moureau.
To prevent central line-associated bloodstream infections (CLABSIs), Moureau urges use of a catheter with the following attributes: Intraluminal and extraluminal protection against a broad range of microbial pathogens Reduction of thrombus accumulation on catheter surfaces with the ability to reduce occlusion and maintain blood return Catheter protection lasting at least 30 days Moureau advises that clinicians should be educated about national guidelines to prevent infection and thrombosis. Guidelines or standards that recommend the use of an anti-infective catheter in certain circumstances have been issued by the CDC, Society for Healthcare Epidemiology of America, Infusion Nursing Society and Infectious Diseases Society of America.
Central line-associated bloodstream infections (CLABSIs) cost $34,508 per incident to treat and are considered “Never Events” - a cost for which hospitals not reimbursed. 4 The average treatment cost for upper-extremity thrombosis is $11,957 per event. 5 Hospitals may also bear additional direct costs associated with extended length of stay (LOS) or indirect costs if their admissions suffer because of poor infection rates. Nearly all Medicare-participating hospitals must publicly report CLABSI rates in their intensive care units. Beginning in 2015, hospitals will be required to report infection data from multiple hospital units, not just ICUs.
Moureau is a Vascular Access Consultant with PICC Excellence, Inc., educator, PRN clinician and is a paid consultant for Teleflex. She is founder of PICC Excellence, Inc., has spoken and been published widely on vascular access issues and has trained thousands of nurses and other medical professionals in PICC placement.
Additional information may be found at arrowintl.com.